格列美脲治疗后胆汁淤积性肝损伤。

Cholestatic liver injury after glimepiride therapy.

作者信息

Chounta Athina, Zouridakis Spyros, Ellinas Christos, Tsiodras Sotirios, Zoumpouli Christina, Kopanakis Stylianos, Giamarellou Helen

机构信息

Hepatology Division, 4th Academic Department of Internal Medicine, Attikon University General Hospital, 7 Orfeos Street, Palaio Faliro, 17564 Athens, Greece.

出版信息

J Hepatol. 2005 Jun;42(6):944-6. doi: 10.1016/j.jhep.2005.02.011. Epub 2005 Apr 7.

DOI:10.1016/j.jhep.2005.02.011

PMID:15885370

Abstract

Drug induced hepatotoxicity has been reported infrequently with sulfonylureas. For glimepiride, a second-generation sulfonylurea there is no report of hepatotoxicity in English literature. A patient with non-insulin-dependent diabetes mellitus who developed cholestatic liver injury soon after initiation of glimepiride therapy is presented. Complete work-up disclosed no other cause for hepatotoxicity including negative serological results for viral hepatitis. Liver biopsy was consistent with drug-induced cholestasis. The patient recovered 50 days after stopping glimepiride with no further recurrences.

摘要

磺酰脲类药物引起的肝毒性报道较少。对于第二代磺酰脲类药物格列美脲，英文文献中尚无肝毒性的报道。本文报告了1例非胰岛素依赖型糖尿病患者，在开始格列美脲治疗后不久出现胆汁淤积性肝损伤。全面检查未发现其他肝毒性原因，包括病毒性肝炎血清学检查结果为阴性。肝活检结果符合药物性胆汁淤积。患者停用格列美脲50天后康复，未再复发。